Cell Source Inc logo

CLCS - Cell Source Inc Share Price

$0.94 0.0  0.0%

Last Trade - 25/11/20

Sector
Healthcare
Size
Micro Cap
Market Cap £21.1m
Enterprise Value £16.4m
Revenue £n/a
Position in Universe 5213th / 6429
Bullish
Bearish
Unlock CLCS Revenue
Momentum
Relative Strength (%)
1m -26.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -39.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, CellSource Inc revenues was not reported. Net loss applicableto common stockholders decreased 11% to $3.9M. Lower netloss reflects Research and development decrease of 39% to$675K (expense), Warrant modification expense decrease from$284K (expense) to $0K, Loss on exchange of notes payablefor Se decrease from $262K (expense) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CLCS Revenue Unlock CLCS Revenue

Net Income

CLCS Net Income Unlock CLCS Revenue

Normalised EPS

CLCS Normalised EPS Unlock CLCS Revenue

PE Ratio Range

CLCS PE Ratio Range Unlock CLCS Revenue

Dividend Yield Range

CLCS Dividend Yield Range Unlock CLCS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CLCS EPS Forecasts Unlock CLCS Revenue
Profile Summary

Cell Source, Inc. is a cell therapy company focused on immunotherapy and regenerative medicine. In cell therapy field, its initial focus is on allogeneic therapies, with a focus on haploidentical transplantations. The Company's subsidiary, Cell Source Limited, commercializes a suite of inventions relating to certain cancer treatments. Its lead prospective product is its Veto Cell immune system management technology. The Company's other planned products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations; Anti-cancer Veto + CAR-T cell therapy for blood cell and solid tumor cancers; Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation; Veto Cell tolerance therapy for non-malignant disorders, and Organ regeneration therapy to address various organ diseases. The Company's Organsource platform addresses the growing shortage of organs for human transplantation.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 6, 2012
Public Since January 14, 2014
No. of Shareholders: 126
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 29,699,509
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CLCS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CLCS
Upcoming Events for CLCS
Frequently Asked Questions for Cell Source Inc
What is the Cell Source Inc share price?

As of 25/11/20, shares in Cell Source Inc are trading at $0.94, giving the company a market capitalisation of £21.1m. This share price information is delayed by 15 minutes.

How has the Cell Source Inc share price performed this year?

Shares in Cell Source Inc are currently trading at $0.94 and the price has moved by 69.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cell Source Inc price has moved by 51.89% over the past year.

What are the analyst and broker recommendations for Cell Source Inc?

There are no analysts currently covering Cell Source Inc.

When will Cell Source Inc next release its financial results?

Cell Source Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Cell Source Inc dividend yield?

Cell Source Inc does not currently pay a dividend.

Does Cell Source Inc pay a dividend?

Cell Source Inc does not currently pay a dividend.

When does Cell Source Inc next pay dividends?

Cell Source Inc does not currently pay a dividend.

How do I buy Cell Source Inc shares?

To buy shares in Cell Source Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cell Source Inc?

Shares in Cell Source Inc are currently trading at $0.94, giving the company a market capitalisation of £21.1m.

Where are Cell Source Inc shares listed? Where are Cell Source Inc shares listed?

Here are the trading details for Cell Source Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: CLCS
What kind of share is Cell Source Inc?

Based on an overall assessment of its quality, value and momentum, Cell Source Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cell Source Inc share price forecast 2020?

We were not able to load any forecast data for Cell Source Inc.

How can I tell whether the Cell Source Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cell Source Inc. Over the past six months, the relative strength of its shares against the market has been -1.55%. At the current price of $0.94, shares in Cell Source Inc are trading at 7.22% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cell Source Inc PE Ratio?

We were not able to find PE ratio data for Cell Source Inc.

Who are the key directors of Cell Source Inc?

Cell Source Inc's management team is headed by:

Itamar Shimrat - CEO
David Zolty - DRC
Ben Friedman - DRC
Dennis Brown - CHM
Who are the major shareholders of Cell Source Inc?

Here are the top five shareholders of Cell Source Inc based on the size of their shareholding:

Friedman (Benzion Abraham) Individual Investor
Percentage owned: 13.85% (4.43m shares)
Yeda Research & Development Co., Ltd. Corporation
Percentage owned: 9.87% (3.16m shares)
Reisner (Yari) Individual Investor
Percentage owned: 3.63% (1.16m shares)
Zolty (David) Individual Investor
Percentage owned: 3.47% (1.11m shares)
Shimrat (Itamar) Individual Investor
Percentage owned: 1.8% (575k shares)
Similar to CLCS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.